Patent intelligence · US
US 9200077
Injectable solution containing therapeutic agent for osteoarthritis
Injectable solution containing therapeutic agent for osteoarthritis
Patent details — US 9200077
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 1, 2015
- Expiration
- Nov 26, 2035
- Applicant
- AXIS
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K9/0019, A61P
Quick answer
US 9200077 (Injectable solution containing therapeutic agent for osteoarthritis) is held by AXIS. Status: granted. Granted Dec 1, 2015. Expires Nov 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXIS
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K9/0019, A61P, A61P19/02, A61P29/00
More from AXIS
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 9200077?
US 9200077 (Injectable solution containing therapeutic agent for osteoarthritis) is held by AXIS. Status: granted. Granted Dec 1, 2015. Expires Nov 26, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9200077?
AXIS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 9200077 expire?
Our index shows an expiration date of Nov 26, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.